In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506

Toxicology

Volumn 131, Issue 2-3, 1998, Pages 175-181

  Al Nasser, Ibrahim A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Adriamycin; Calcium; Cyclosporin A; Heart mitochondria; Tacrolimus (FK506)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CYCLOSPORIN A; DOXORUBICIN; LACTATE DEHYDROGENASE ISOENZYME; TACROLIMUS;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOTOXICITY; CELL MEMBRANE PERMEABILITY; HEART MITOCHONDRION; INTRAVENOUS DRUG ADMINISTRATION; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECTROPHOTOMETRY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CALCIUM; CYCLOSPORINE; DOXORUBICIN; HEART; MITOCHONDRIA; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 0032538809     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(98)00128-0     Document Type: Article

References (37)

1. Al-Nasser I. Prevention of adriamycin aglycone-induced changes of inner mitochondrial membrane permeability by cyclosporin A. Med. Sci. Res. 25:1997;249-251.
2. 2+-loaded rat renal cortex mitochondria. Med. Sci. Res. 23:1995;391-393.
3. 2+-induced permeabilisation of ratliver mitochondria. Biochem. J. 239:1986;19-24.
4. 2+-activated inner-membrane pore of heart mitochondria. Eur. J. Biochem. 230:1995;1125-1131.
5. Antoni F., Shipston M., Smith S. Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells. Biochem. Biophys. Res. Comm. 194(3):1993;226-233.
6. Bergmeyer H.U., Bernt E. Lactate dehydrogenase isoenzymes, UV assay after separation on DEAE-Sephadex. Bergmeyer H.U. Methods of Enzymatic Analysis. 1974;590 Verlag Chemie Weinheim/Academic Press, New York.
7. Bernardi P., Petronili V. The permeability transition pore as a mitochondrial calcium release channel: A critical appraisal. J. Bioenerg. Biomembr. 28:1996;77-90.
8. 2+. An alternate mechanism for the cardiotoxicity of doxorubicin. Toxicol. Appl. Pharmacol. 107:1991;117-128.
9. 2+ increase by doxorubicin in cardiac myocytes. Biochem. J. 281:1992;871-878.
10. 2+ overload. Eur. J. Biochem. 178:1988;489-501.
11. Eckenoff R., Somiyo A. Cardiac mitochondrial calcium content during fatal doxorubicin toxicity. Toxicol. Appl. Pharmacol. 97:1989;167-172.
12. Fruman D., Klee C., Bierer B., Burakoff S. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin. Proc. Natl. Acad. Sci. USA. 89:1992;3686-3690.
13. Griffiths E., Halestrap A. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Biochem. J. 274:1991;611-614.
14. Halestrap A., Connern C., Griffiths E., Kerr P. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reprefusion injury. Mol. Cell Biochem. 174:1997;167-172.
15. 2+ induced large-amplitude swelling of liver and heart mitochondria by cyclosporin A is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem. J. 268:1990;153-160.
16. Kachmar J., Moss D. Enzymes. Teitz W. Fundamentals of Clinical Chemistry. 1982;565-595 Saunders, Philadelphia.
17. Kamo N., Muratsugo M., Ruyi H., Kobatake J. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenylphosphonium and relation between proton electrochemical potential and phosphorylation potential in steady state. J. Membr. Biol. 48:1979;105-121.
18. Keizer H., Pinedo H., Schuurhuis G., Joenje H. Doxorubicin: a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther. 47:1990;219-231.
19. Koroger A., Klingenberg M. A modified biuret method for the determination of protein. Biochem. Z. 344:1966;317-338.
20. Kunz J., Hall M. Cyclosporin A, FK506 and rapamycin: More than just immunosuppression. Trends Biochem. Sci. 18:1993;334-338.
21. Meller F., Young D., Ward J. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive failure) in rats. Cancer Res. 237:1977;2705-2713.
22. m overload in rat heart. Am. J. Physiol. 271:1996;H2145-H2153.
23. Nicolli A., Basso E., Petronilli V., Wenger R., Bernardi P. Interactions of cyclophilin with mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. J. Biol. Chem. 271:1996;2185-2191.
24. Novgordov S., Gudz T. Permeability transition pore of the inner mitochondrial membrane can operate in two open states with different selectivities. J. Bioenerg. Biomembr. 28:1996;139-146.
25. Ollinger K., Brunmark A. Effect of different oxygen pressure and N,N Diphenyl-p-phenylenediamine on adriamycin toxicity to cultured neonatal rat heart myocytes. Biochem. Pharmacol. 48:1994;1707-1715.
26. Olsen H., Capen C. Chronic cardiotoxicity of adriamycin in the rat: morphologic and biochemical investigations. Toxicol. Appl. Pharmacol. 44:1978;606-616.
27. Olsen R., Mushlin P. Doxorubicin cardiotoxicity, analysis of prevailing hypothesis. FASEB J. 4:1990;2076-2086.
28. Peng C., Kane J., Slaub K., Murphy M. Improvement of mitochondrial energy production in ischaemic myocardium by in vivo infusion of ruthenium red. Cardiovasc. Pharmacol. 2:1980;45-54.
29. Petit P., Susin S., Zamzami N., Mignotte B., Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett. 396:1996;7-13.
30. Porta E., Joun N., Matsumura L., Nakasone B., Sablan H. Acute adriamycin cardiotoxicity in rat. Res. Commun. Chem. Pathol. Pharmacol. 41:1983;125-137.
31. Retiman S., Frankel S. A colourimetic method for determination of serum glutamic oxaloacetic and glutamic pyruvic transaminase. Am. J. Clin. Pathol. 28:1957;56-60.
32. Schreiber S., Crabtree G. The mechanism of action of cyclosporin A and FK506. Immunol. Today. 13:1992;136-142.
33. Singal P., Iliskovic N., Tli T., Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11(12):1997;931-936.
34. Singh J., Garge K., Garge D., Chugh K., Lal H. Effect of aspartate and glutamate on experimental myocardial infarction in rats. Indian J. Exp. Biol. 27:1989;621-624.
35. 2+ from rat heart mitochondria: induction by adriamycin aglycone. Biochem. Pharmacol. 37:1988;803-812.
36. Wiederrecht G., Lam E., Hung S., Marlin M., Sigal N. The mechanism of action of FK506 and cyclosporin A. Ann. NY Acad. Sci. 696:1993;9-19.
37. Zoraiti M., Szabo I. The mitochondrial permeability transition. Biochem. Biophys. Acta. 1241:1995;139-176.